Globeflex Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Globeflex Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,400	Closed	-$115K	–	502
2016 Q4	$115K	Buy	+2,400	New	+$95K	0.03%	362
2016 Q1	–	Sell	-3,300	Closed	-$204K	–	466
2015 Q4	$204K	Hold	3,300	–	–	0.05%	311
2015 Q3	$133K	Sell	3,300 -8,300	-72%	-$430K	0.03%	393
2015 Q2	$668K	Sell	11,600 -18,100	-61%	-$1.15M	0.12%	283
2015 Q1	$1.89M	Sell	29,700 -100	-0.3%	-$6.79K	0.36%	74
2014 Q4	$1.84M	Sell	29,800 -23	-0.1%	-$1.14K	0.36%	83
2014 Q3	$1.16M	Sell	29,823 -96	-0.3%	-$3.4K	0.13%	184
2014 Q2	$1.03M	Buy	29,919 +4,319	+17%	+$136K	0.11%	224
2014 Q1	$1.11M	Sell	25,600 -100	-0.4%	-$4.85K	0.13%	205
2013 Q4	$1.02M	Hold	25,700	–	–	0.12%	209
2013 Q3	$964K	Hold	25,700	–	–	0.12%	212
2013 Q2	$690K	Buy	+25,700	New	+$547K	0.09%	247

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Globeflex Capital's IONS Position: Q1 2017 in Review

Globeflex Capital sold out of Ionis Pharmaceuticals (IONS) in Q1 2017, closing a stake of 2,400 shares — an estimated $115K sold.

Globeflex Capital first reported a position in IONS in Q2 2013 and held it in 12 quarters. The position peaked at $1.89M in Q1 2015. 270 funds tracked by Wall St. Rank hold IONS as of Q1 2017.

Globeflex Capital reported no remaining Ionis Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Globeflex Capital sold 2,400 Ionis Pharmaceuticals shares in Q1 2017, an estimated $115K.
Globeflex Capital first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 12 quarters.
Globeflex Capital's Ionis Pharmaceuticals position peaked at $1.89M in Q1 2015.
270 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2017.

Based on Globeflex Capital's 13F filing for Q1 2017, filed 12 May 2017.